Association between cytomegalovirus disease and chronic rejection in kidney transplant recipients

Transplantation

Volumn 68, Issue 12, 1999, Pages 1879-1883

  Humar, Abhinav ^a   Gillingham, Kristen J ^a   Payne, William D ^a   Dunn, David L ^a   Sutherland, David E R ^a   Matas, Arthur J ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AZATHIOPRINE; CYCLOSPORIN A; GANCICLOVIR; LYMPHOCYTE ANTIBODY; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; PREDNISONE; THYMOCYTE ANTIBODY;

ADULT; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; PATHOGENESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECIPIENT; RISK FACTOR; VIRUS LATENCY; VIRUS VIRULENCE;

EID: 0033611067     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199912270-00011     Document Type: Conference Paper

References (22)

1. Schweitzer EJ, Matas AJ, Gillingham KJ, et al. Causes of renal allograft loss: progress in the 1980s, challenges for the 1990s. Ann Surg 1991; 214: 679.
2. Massy ZA, Guijarro C, Wiederkehr MR, Ma JZ, Kasiske BL. Chronic renal allograft rejection: immunologic and nonimmunologic risk factors. Kidney Int 1996; 49: 518.
3. Brenner BM, Cohen RA, Milford EL. In renal transplantation, one size may not fit all. J Am Soc Nephrol 1992; 3(2): 162.
4. Matas AJ. Risk factors for chronic rejection: a clinical perspective. Transplant Immunol 1998; 6: 1.
5. Almond PS, Matas A, Gillingham K, et al. Risk factors for chronic rejection in renal allograft recipients. Transplantation 1993; 55: 752.
6. Terasaki PI, Koyama H, Cecka JM, Gjertson DW. The hyperfiltration hypothesis in human renal transplantation. Transplantation 1994; 57: 1450.
7. Yuge J, Cecks JM. Sex and age effects in renal transplantation. In: Terasaki PI, ed. Clinical transplants 1991. Los Angeles: UCLA Tissue Typing Laboratory, 1992: 257.
8. Bock GH, Sullivan EK, Miller D, et al. Cytomegalovirus infections following renal transplantation - effects of antiviral prophylaxis: a report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Nephrol 1997; 11: 665.
9. Akposso K, Rondeau E, Haymann JP, Peraldi MN, Marlin C, Sraer JD. Long-term prognosis of renal transplantation after preemptive treatment of cytomegalovirus infection. Transplantation' 1997; 63: 974.
10. Perez RV, Matas AJ, Gillingham KJ, et al. Lessons learned and future hopes: three thousand renal transplants at the University of Minnesota. In: Terasaki PI, ed. Clinical Transplants 1990. Los Angeles: UCLA Tissue Typing Laboratory, 1991: 217.
11. Johnson EM, Canafax DM, Gillingham KJ, et al. Effect of early cyclosporine levels on kidney allograft rejection. Clin Transplant 1997; 11(6): 552.
12. Balfour HH, Chace BA, Stapleton JT. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med 1989; 320: 1381.
13. Everett JP, Hershberger RE, Norman DJ, et al. Prolonged cytomegalovirus infection with viremia is associated with development of cardiac allograft vasculopathy. J Heart Lung Transplant 1992; 11: S133.
14. Keenan RJ, Lega ME, Dummer JS, et al. Cytomegalovirus serologic status and postoperative infection correlated with risk of developing chronic rejection after pulmonary transplantation. Transplantation 1991; 51: 433.
15. Arnold JC, Portmann BC, O'Grady JG, Naoumov NV, Alexander GJM, Williams R. Cytomegalovirus infection persists in the liver graft in the vanishing bile duct syndrome. Hepatology 1992; 16: 285.
16. Paya CV, Wiesner RH, Hermans PE, et al. Lack of association between cytomegalovirus infection, HLA matching and the vanishing bile duct syndrome after liver transplantation. Hepatology 1992; 16: 66.
17. Rubin RH, Tolkoff-Rubin NE, Oliver D, et al. Multicenter seroepidemiologic study of the impact of cytomegalovirus infection on renal transplantation. Transplantation 1985; 40: 243.
18. Fryd DS, Peterson PK, Ferguson RM, et al. Cytomegalovirus as a risk factor in renal transplantation. Transplantation 1980; 30: 436.
19. Dunn DL, Mayoral JL, Gillingham KJ, et al. Treatment of invasive CMV disease in solid organ transplant patients with ganciclovir. Transplantation 1991; 51: 98.
20. Humar A, Uknis M, Carlone-Jambor C, Gruessner RW, Dunn DL, Matas A. Cytomegalovirus disease recurrence after ganciclovir treatment in kidney and kidney-pancreas transplant recipients. Transplantation 1999; 67: 94.
21. Humar A, Kerr S, Hassoun A, et al. Features of acute rejection that predict increased risk for chronic rejection. Transplant Proc 1999; 31: 1302.
22. Humar A, Johnson EM, Payne WD, et al. Effect of initial slow graft function on renal allograft rejection and survival. Clin Transplant 1997; 11(6): 623.